338840 — Y Biologics Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapSucker Stock

Annual cashflow statement for Y Biologics, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	ARS	Annual Audited Accounts	Annual Audited Accounts
Standards:	—	—	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	-17,071	-18,804	-20,871	-6,442	-42,025
Depreciation
Amortisation
Non-Cash Items	1,223	3,469	12,597	-334	33,420
Unusual Items
Other Non-Cash Items
Changes in Working Capital	4,364	2,269	-1,688	595	832
Change in Accounts Receivable
Change in Prepaid Expenses
Change in Accounts Payable
Change in Accrued Expenses
Change in Payable / Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	-9,168	-10,105	-7,607	-4,143	-5,840
Capital Expenditures	-7,571	-1,097	-196	-2,860	-1,425
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-325	338	3,911	-2,562	-660
Sale of Fixed Assets
Sale/Maturity of Investment
Change in Net Investments
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-7,896	-759	3,715	-5,422	-2,084
Financing Cash Flow Items	—	—	—	65	0
Other Financing Cash Flow
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	248	6,896	11,782	-1,928	37,763
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	-16,516	-4,259	7,922	-11,452	29,839